XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Balance Sheets - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 18,804,602 $ 46,329,359
Short-term investments 148,668,866 206,669,397
Prepaid expenses and other current assets 5,114,873 50,130,481
Prepaid expenses and other current assets from affiliated entities 34,923 375,227
Total current assets 174,767,197 315,242,680
Fixed assets, net 5,632,511 7,727,997
Investment in affiliated entity 2,994,900 2,007,142
Intangible assets, net 0 2,129,861
Goodwill 0 10,513,371
Operating lease right-of-use assets 9,097,275 10,228,207
Other assets 605,315 684,044
Total assets 193,097,198 348,533,302
Current liabilities:    
Accrued clinical trial expenses 5,011,185 10,594,073
Operating lease liability 2,117,971 2,803,973
Grant funding liability 3,806,161 2,475,031
Grant funding liability from affiliated entity 21,918 87,673
Convertible senior notes 16,488,329 0
Total current liabilities 43,711,026 96,868,074
Convertible senior notes 0 16,614,840
Operating lease liability, net of current portion 11,194,413 12,655,586
Deferred tax liabilities 32,046 32,046
Total liabilities 54,937,485 126,170,546
Stockholders’ equity:    
Preferred stock 0 0
Common stock 269,730 253,090
Additional paid-in capital 1,736,602,555 1,710,656,191
Accumulated deficit (1,597,961,498) (1,487,847,784)
Accumulated other comprehensive loss (751,074) (698,741)
Total Inovio Pharmaceuticals, Inc. stockholders’ equity 138,159,713 222,362,756
Total liabilities and stockholders’ equity 193,097,198 348,533,302
Nonrelated Party    
Current assets:    
Accounts receivable 0 1,701,726
Current liabilities:    
Accounts payable and accrued expenses 15,553,742 79,686,885
Related Party    
Current assets:    
Accounts receivable 2,143,933 10,036,490
Current liabilities:    
Accounts payable and accrued expenses $ 711,720 $ 1,220,439